NCT03296059 is a NA clinical trial of conventional treatment with RBC transfusion in Red Blood Cells(RBC), sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

What drugs are being tested in NCT03296059?

Interventions in NCT03296059: conventional treatment with RBC transfusion, conventional treatment.

What condition does NCT03296059 study?

NCT03296059 studies Red Blood Cells(RBC), Acute Respiratory Distress Syndrome (ARDS).

Is NCT03296059 still recruiting?

NCT03296059 is currently status unknown. Last updated 25 October 2022.

Last reviewed 2022-10-25 · How we verify

NCT03296059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates

Status unknown NA Last updated 25 October 2022

What this trial tests

NA trial testing conventional treatment with RBC transfusion in Red Blood Cells(RBC) in 100 participants. Status unknown.

Timeline

1 October 2017

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 October 2017
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

conventional treatment with RBC transfusion
conventional treatment — full drug profile →

Conditions studied

Red Blood Cells(RBC) — all drugs for Red Blood Cells(RBC) →
Acute Respiratory Distress Syndrome (ARDS) — all drugs for Acute Respiratory Distress Syndrome (ARDS) →

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

Adults 30 Minutes to 1 Month, any sex, with Red Blood Cells(RBC) or Acute Respiratory Distress Syndrome (ARDS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017. The death rate is over 50%.There are no special treatments for acute respiratory distress syndrome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Radford M, Estcourt LJ, Sirotich E, Pitre T, et al · · 2024 · cited 8× · PMID 38780066 · DOI 10.1002/14651858.cd011305.pub3

Verify or expand the search:

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03296059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Last refreshed: 25 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03296059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing